https://biotechmorning.com/news/satellos-muscle-remodeling-adult-duchenne Biotech Morning en 2026-07-09T14:26:15.884Z The Muscle Disease That Only Gets Worse Just Got Better https://biotechmorning.com/news/trump-tax-bill-biotech-giveth-taketh Biotech Morning en 2026-07-09T14:25:24.329Z The Tax Bill That Giveth and Taketh Away From Biotech https://biotechmorning.com/news/astrazeneca-sino-biopharma-copd-deal Biotech Morning en 2026-07-09T14:24:31.243Z AstraZeneca Just Paid $200M to Pick a Fight with Merck Over Your Lungs https://biotechmorning.com/news/sino-biopharm-lanova-acquisition-bispecific-antibody Biotech Morning en 2026-07-09T14:23:38.295Z The $500 Million Shortcut That Bought a Billion-Dollar Biotech https://biotechmorning.com/news/ebola-jumps-new-province-no-weapons Biotech Morning en 2026-07-09T14:22:44.274Z Ebola Just Jumped to a New Province. Nobody Has the Right Weapons. https://biotechmorning.com/news/fda-commissioner-search-2026-white-house-contenders Biotech Morning en 2026-07-09T14:21:47.911Z The FDA Needs a New Boss. Nobody Knows Who It'll Be. https://biotechmorning.com/news/tavneos-nejm-retraction-advocate-trial Biotech Morning en 2026-07-09T14:20:56.487Z The Billion-Dollar Drug Built on a Paper That No Longer Exists https://biotechmorning.com/news/gsk-alector-700-million-alzheimers-deal-dead Biotech Morning en 2026-07-09T14:20:06.870Z GSK Just Lit $700 Million on Fire (and Walked Away) https://biotechmorning.com/news/prime-medicine-beam-patent-ruling-gene-editing Biotech Morning en 2026-07-09T14:19:10.260Z The Gene-Editing Turf War That Could Redraw the Entire CRISPR Map https://biotechmorning.com/news/penicillin-recall-syphilis-crisis Biotech Morning en 2026-07-08T14:25:33.912Z America's Only Syphilis Drug for Pregnant Women Just Vanished From Shelves https://biotechmorning.com/news/astrazeneca-amyloidosis-drug-phase-3-failure Biotech Morning en 2026-07-08T14:24:46.049Z AstraZeneca's Amyloidosis Drug Just Flopped. But There's a Plot Twist. https://biotechmorning.com/news/novo-nordisk-hims-wegovy-ozempic-telehealth-deal Biotech Morning en 2026-07-08T14:23:56.300Z From Lawsuit to Love Story: How Novo Nordisk and Hims Buried the Hatchet https://biotechmorning.com/news/intellia-crispr-trial-pause-safety-concern Biotech Morning en 2026-07-08T14:22:59.999Z Intellia's CRISPR Dream Just Hit a Wall https://biotechmorning.com/news/ionis-tryngolza-expanded-approval-blockbuster Biotech Morning en 2026-07-08T14:22:07.998Z Ionis Just Turned a Rare Disease Drug Into a $3 Billion Opportunity https://biotechmorning.com/news/fda-cder-staff-exodus-drug-approvals-at-risk Biotech Morning en 2026-07-08T14:21:15.515Z The FDA Is Running Out of People Who Know How to Approve Your Drugs https://biotechmorning.com/news/kailera-oral-obesity-pill-phase-3-china Biotech Morning en 2026-07-08T14:20:19.736Z The Obesity Pill That Could Crash Big Pharma's Party https://biotechmorning.com/news/lilly-ajax-2-3b-jak2-inhibitor-deal Biotech Morning en 2026-07-08T14:19:27.242Z Lilly Just Paid $2.3B for a Phase 1 Drug. Here's the Bet. https://biotechmorning.com/news/vera-therapeutics-atacicept-trutakna-iga-nephropathy-fda-approval Biotech Morning en 2026-07-08T14:18:36.440Z A Kidney Disease With No Good Options Just Got Its Sixth FDA-Approved Drug